Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aldosterone (targeted delivery) is a preclinical-stage therapeutic candidate being developed by PIF Partners. It utilizes a proprietary platform technology designed to deliver aldosterone specifically to activated macrophages. By targeting these cells, the drug aims to modulate macrophage-mediated inflammatory responses while potentially minimizing systemic side effects associated with mineralocorticoid receptor activation in other tissues. The development is currently in the preclinical phase, with no specific indications disclosed beyond the general targeting of activated macrophages.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aldosterone (targeted delivery).